Taking everything into account, IRIX scores 1 out of 10 in our fundamental rating. IRIX was compared to 185 industry peers in the Health Care Equipment & Supplies industry. Both the profitability and financial health of IRIX have multiple concerns. IRIX does not seem to be growing, but still is valued expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -17.94% | ||
| ROE | -108.67% | ||
| ROIC | N/A |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 38.18% |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.79 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -2.13 |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.94 | ||
| Quick Ratio | 1.35 |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
NASDAQ:IRIX (1/9/2026, 8:00:02 PM)
1.15
-0.04 (-3.36%)
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 0.39 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 4.22 | ||
| P/tB | 7.45 | ||
| EV/EBITDA | N/A |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -17.94% | ||
| ROE | -108.67% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 38.18% | ||
| FCFM | N/A |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.79 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 9.07% | ||
| Cap/Sales | 0.09% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 1.94 | ||
| Quick Ratio | 1.35 | ||
| Altman-Z | -2.13 |
ChartMill assigns a fundamental rating of 1 / 10 to IRIX.
ChartMill assigns a valuation rating of 0 / 10 to IRIDEX CORP (IRIX). This can be considered as Overvalued.
IRIDEX CORP (IRIX) has a profitability rating of 1 / 10.
The Earnings per Share (EPS) of IRIDEX CORP (IRIX) is expected to grow by 49% in the next year.